Abbott Laboratories stock weighs Amulet 360 data ahead of U.S. review

Published on 11/13/2026 at 13:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott Laboratories stock remains in focus after one-year VERITAS results for its investigational Amulet 360 implant. U.S. clearance remains pending.

Amulet 360 data sharpen catalyst

Abbott reported one-year VERITAS results for its investigational left atrial appendage device.
The study supports the device's closure performance while U.S. regulatory clearance remains pending.
The implant's European approval and broader cardiology portfolio keep regulatory execution in focus.

Abbott Laboratories, US0028241000, Illustration mit AI erstellt.

Abbott Laboratories reported one-year results from the VERITAS study on November 2, 2026, adding a new clinical milestone for its investigational Amulet 360 left atrial appendage occluder. The company said the results were presented at the Transcatheter Cardiovascular Therapeutics conference on November 1 and published simultaneously in JACC: Cardiovascular Interventions. The Abbott press release described high closure rates and a low incidence of stroke in patients with non-valvular atrial fibrillation.

Amulet 360 achieved complete left atrial appendage closure in 96.3 percent of patients evaluated by transesophageal echocardiography, according to Abbott. More than 98 percent of patients remained free from ischemic stroke or systemic embolism through one year, while more than 99 percent avoided pericardial effusion requiring intervention. Major bleeding events were not reported in 93.4 percent of patients during the first year.

Clinical progress meets regulatory uncertainty

The VERITAS study enrolled more than 450 patients at over 30 hospitals in the United States, Canada and Europe. Abbott designed the next-generation device with a softer, more conformable implant body and an outer disc that provides a second sealing layer for a wider range of left atrial appendage anatomies.

The commercial opportunity remains conditional. Amulet 360 is approved for investigational use only in the United States, while Abbott said it received CE Mark approval in August 2026. U.S. clearance therefore remains the next regulatory step before the device can contribute to the company's American commercial portfolio.

For investors, the results strengthen the clinical case for Abbott's cardiology franchise but do not remove execution risk. The study's one-year findings address closure and clinical outcomes; regulatory timing and broader adoption will determine whether the program develops into a material growth driver. Abbott also links the device with its wider atrial-fibrillation offering, which includes ablation and cardiac-mapping technologies.

Abbott Laboratories stock traded at 97.50 euros on Lang & Schwarz at 1:01 p.m. CET on Friday, November 13, 2026, 0.39 percent below the Xetra close of Thursday, November 12, 2026. The Xetra close was 97.88 euros, according to Macroaxis, which reported the November 12 closing price and trading range.